Hello!
Here is a quick summary.
All infants of HBsAg-positive women should receive HBV vaccination ± hepatitis B immunoglobulin.
Pregnant women who have hepatitis B virus DNA levels greater than 200,000 IU/mL at 24 to 28 weeks' gestation should be treated with antivirals to prevent vertical transmission during delivery.
Antivirals studied in pregnant women: Lamivudine, telbivudine, and tenofovir.
Antiviral therapy was discontinued at birth to 3 months postpartum. With discontinuation of treatment, women should be monitored for ALT flares every 3 months for 6 months.
Breastfeeding is not contraindicated - antivirals are minimally excreted in breast milk.
C-section is not indicated - insufficient data to support benefit.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987259/
-IkaN
Here is a quick summary.
All infants of HBsAg-positive women should receive HBV vaccination ± hepatitis B immunoglobulin.
Pregnant women who have hepatitis B virus DNA levels greater than 200,000 IU/mL at 24 to 28 weeks' gestation should be treated with antivirals to prevent vertical transmission during delivery.
Antivirals studied in pregnant women: Lamivudine, telbivudine, and tenofovir.
Antiviral therapy was discontinued at birth to 3 months postpartum. With discontinuation of treatment, women should be monitored for ALT flares every 3 months for 6 months.
Breastfeeding is not contraindicated - antivirals are minimally excreted in breast milk.
C-section is not indicated - insufficient data to support benefit.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987259/
-IkaN
I think you need to rethink regarding title of this blog
ReplyDeleteHaha whoops my bad. Will correct it :)
Delete